Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2021-04-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
祥生医疗监事会关于公司2021年限制性股票激励计划（草案）的核查意见
Regulatory Filings Classification · 90% confidence The document is a supervisory board's verification opinion on the company's 2021 restricted stock incentive plan draft. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and the plan's alignment with company and legal requirements. It does not contain financial statements or results, nor is it an announcement of a meeting or voting results. It is a regulatory compliance and governance-related document focused on stock incentive plans. This fits best under Regulatory Filings (RNS) as it is a compliance and verification statement rather than a full report or announcement.
2021-04-23 Chinese
祥生医疗2021年第一季度报告正文
Interim / Quarterly Report Classification · 95% confidence The document is titled '2021 年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data such as total assets, net assets, cash flow, revenue, net profit, earnings per share, and shareholder information. The document also includes notes on non-recurring gains and losses, shareholder structure, and important financial changes. The presence of comprehensive financial statements and analysis for a quarter indicates this is a quarterly financial report. The document length is 4446 characters, which is sufficient to contain substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-23 Chinese
容诚会计师事务所（特殊普通合伙）关于无锡祥生医疗科技股份有限公司募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds." It is issued by an accounting firm (容诚会计师事务所) and addresses the company's raised funds management and usage for the year 2020. The document references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the management and disclosure of raised funds. It includes detailed financial data on the raised funds, their storage, usage, and related cash management activities. The document is a standalone audit/verification report focusing on the raised funds usage and compliance, not a full annual report or interim financial report. It is not an announcement or a brief notice but a substantive verification report. Therefore, it fits the category of an Audit Report / Information (AR). FY 2020
2021-04-23 Chinese
祥生医疗独立董事关于第二届董事会第四次会议相关议案的独立意见
Remuneration Information Classification · 95% confidence The document is an independent director's opinion on various proposals discussed at the company's second board's fourth meeting. It covers topics such as the 2021 remuneration plan for directors and senior management, appointment of the 2021 audit firm, 2020 profit distribution plan, use of raised funds, expected related party transactions, accounting policy changes, stock incentive plans, and other governance matters. The document references the 2020 annual shareholders meeting for approval of these proposals. It is not a full annual report or audit report but rather an opinion on board meeting proposals, including remuneration and governance issues. This fits best under the category of Remuneration Information (DEF 14A), as it details compensation plans and related governance opinions, and also includes other board meeting agenda items. The document is over 5,000 characters and contains substantive content, not just an announcement or certification. Therefore, the classification is DEF 14A with high confidence.
2021-04-23 Chinese
祥生医疗关于作废处理部分限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Wuxi Xiangsheng Medical Technology Co., Ltd. regarding the cancellation of certain restricted stocks under the 2019 restricted stock incentive plan. It details the background, reasons, quantities, and effects of the cancellation, along with opinions from the supervisory board, independent directors, and legal counsel. The content focuses on changes related to stock incentives and does not contain financial statements or quarterly/yearly financial results. It is not a full financial report but an announcement about changes in share-based compensation. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share incentive plan adjustments and does not fit other more specific categories like Share Issue/Capital Change (SHA) because it is about cancellation of restricted stock awards rather than new share issuance or capital changes. The document length is under 5,000 characters, and it is a detailed announcement rather than a report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2021-04-23 Chinese
祥生医疗独立董事关于第二届董事会第四次会议相关议案的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement of prior approval opinions by independent directors regarding proposals to be reviewed at the company's board meeting. It references internal governance documents and regulatory guidelines related to independent directors and associated transactions. The content focuses on governance and board-level decisions rather than financial results or audit reports themselves. The document length is short (1183 characters) and does not contain financial statements or detailed financial data. It is not an announcement of voting results or a proxy solicitation but rather an internal governance opinion document. Therefore, the best fitting category is Board/Management Information (MANG), which covers announcements related to board or senior management matters, including independent director opinions and board meeting proposals.
2021-04-23 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.